{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:02:04Z","timestamp":1789552924104,"version":"build-2803163510"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100015381","name":"Instituto Nacional De Salud P\u00fablica","doi-asserted-by":"publisher","award":["2013-215484."],"award-info":[{"award-number":["2013-215484."]}],"id":[{"id":"10.13039\/501100015381","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04521-3","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:36:48Z","timestamp":1789544208000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prophylactic and therapeutic effects of aspirin in cancer"],"prefix":"10.1007","author":[{"given":"Lizet D\u00edaz","family":"Peralta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika Itayetzi Hern\u00e1ndez","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Isabel Burguete","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Luis Reyna","family":"Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6017-4174","authenticated-orcid":false,"given":"Victor Hugo Berm\u00fadez","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"4521_CR1","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3389\/fimmu.2017.00261","volume":"8","author":"AP Cadavid","year":"2017","unstructured":"Cadavid AP. Aspirin: the mechanism of action revisited in the context of pregnancy complications. Front Immunol. 2017;8:261.","journal-title":"Front Immunol"},{"issue":"5","key":"4521_CR2","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/bjh.14520","volume":"177","author":"MJR Desborough","year":"2017","unstructured":"Desborough MJR, Keeling DM. The aspirin story - from willow to wonder drug. Br J Haematol. 2017;177(5):674\u201383.","journal-title":"Br J Haematol"},{"key":"4521_CR3","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.2147\/TCRM.S92222","volume":"11","author":"YH Mekaj","year":"2015","unstructured":"Mekaj YH, Daci FT, Mekaj AY. New insights into the mechanisms of action of aspirin and its use in the prevention and treatment of arterial and venous thromboembolism. Ther Clin Risk Manag. 2015;11:1449\u201356.","journal-title":"Ther Clin Risk Manag"},{"key":"4521_CR4","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.14309\/ajg.0000000000002695","volume":"119","author":"S Nafisi","year":"2024","unstructured":"Nafisi S, St\u00f8er NC, Veier\u00f8d MB, et al. Low-dose aspirin and prevention of colorectal cancer: evidence from a nationwide registry-based cohort in Norway. Am J Gastroenterol. 2024;119:1402\u201311.","journal-title":"Am J Gastroenterol"},{"key":"4521_CR5","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.annonc.2020.02.012","volume":"31","author":"C Bosetti","year":"2019","unstructured":"Bosetti C, Santucci C, Gallus S, Martinetti M, La Vecchia C. Aspirin and the risk of colorectal and other digestive tract cancers: an updated meta-analysis through 2019. Ann Oncol. 2019;31:558\u201368.","journal-title":"Ann Oncol"},{"key":"4521_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vph.2018.10.008","volume":"113","author":"MR Montinari","year":"2019","unstructured":"Montinari MR, Minelli S, De Caterina R. The first 3500 years of aspirin history from its roots - a concise summary. Vascul Pharmacol. 2019;113:1\u20138.","journal-title":"Vascul Pharmacol"},{"key":"4521_CR7","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s10555-017-9675-z","volume":"36","author":"A Ornelas","year":"2017","unstructured":"Ornelas A, Zacharias-Millward N, Menter DG, et al. Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention. Cancer Metastasis Rev. 2017;36:289\u2013303.","journal-title":"Cancer Metastasis Rev"},{"issue":"4","key":"4521_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ph11040101","volume":"11","author":"A Pannunzio","year":"2018","unstructured":"Pannunzio A, Coluccia M. Cyclooxygenase-1 (COX-1) and COX-1 inhibitors in cancer: a review of oncology and medicinal chemistry literature. Pharmaceuticals (Basel). 2018;11(4):101.","journal-title":"Pharmaceuticals (Basel)"},{"key":"4521_CR9","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12935-015-0260-7","volume":"15","author":"B Liu","year":"2015","unstructured":"Liu B, Qu L, Yan S. Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity. Cancer Cell Int. 2015;15:106.","journal-title":"Cancer Cell Int"},{"key":"4521_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.4103\/aam.aam_56_18","volume":"18","author":"N Singh","year":"2019","unstructured":"Singh N, Baby D, Rajguru JP, Patil PB, Thakkannavar SS, Pujari VB. Inflammation and cancer. Ann Afr Med. 2019;18:121\u20136.","journal-title":"Ann Afr Med"},{"key":"4521_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110389","volume":"129","author":"S Li","year":"2020","unstructured":"Li S, Jiang M, Wang L, Yu S. Combined chemotherapy with cyclooxygenase-2 (COX-2) inhibitors in treating human cancers: recent advancement. Biomed Pharmacother. 2020;129:110389.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"4521_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/wsbm.1596","volume":"15","author":"A Sahu","year":"2023","unstructured":"Sahu A, Raza K, Pradhan D, Jain AK, Verma S. Cyclooxygenase-2 as a therapeutic target against human breast cancer: A comprehensive review. WIREs Mech Dis. 2023;15(3):e1596.","journal-title":"WIREs Mech Dis"},{"issue":"3-4","key":"4521_CR13","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s10555-011-9303-2","volume":"30","author":"J Reader","year":"2011","unstructured":"Reader J, Holt D, Fulton A. Prostaglandin E2 EP receptors as therapeutic targets in breast cancer. Cancer Metastasis Rev. 2011;30(3\u20134):449\u201363.","journal-title":"Cancer Metastasis Rev"},{"key":"4521_CR14","volume":"9","author":"F Finetti","year":"2020","unstructured":"Finetti F, Travelli C, Ercoli J, Colombo G, Buoso E, Trabalzini L. Prostaglandin E2 and cancer: insight into tumor progression and immunity. Biology (Basel). 2020;9:434.","journal-title":"Biology (Basel)"},{"key":"4521_CR15","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1158\/1940-6207.CAPR-16-0094","volume":"9","author":"O Boutaud","year":"2016","unstructured":"Boutaud O, Sosa IR, Amin T, et al. Inhibition of the biosynthesis of prostaglandin E2 by low-dose aspirin: implications for adenocarcinoma metastasis. Cancer Prev Res (Phila). 2016;9:855\u201365.","journal-title":"Cancer Prev Res (Phila)"},{"key":"4521_CR16","doi-asserted-by":"publisher","first-page":"5239","DOI":"10.1111\/bph.13331","volume":"172","author":"G O'Callaghan","year":"2015","unstructured":"O\u2019Callaghan G, Houston A. Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets? Br J Pharmacol. 2015;172:5239\u201350.","journal-title":"Br J Pharmacol"},{"issue":"3","key":"4521_CR17","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1124\/pharmrev.123.000901","volume":"76","author":"A Santiso","year":"2024","unstructured":"Santiso A, Heinemann A, Kargl J. Prostaglandin E2 in the tumor microenvironment, a convoluted affair mediated by EP receptors 2 and 4. Pharmacol Rev. 2024;76(3):388\u2013413.","journal-title":"Pharmacol Rev"},{"issue":"1","key":"4521_CR18","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ygyno.2017.10.026","volume":"148","author":"T Takiuchi","year":"2018","unstructured":"Takiuchi T, Blake EA, Matsuo K, Sood AK, Brasky TM. Aspirin use and endometrial cancer risk and survival. Gynecol Oncol. 2018;148(1):222\u201332.","journal-title":"Gynecol Oncol"},{"key":"4521_CR19","doi-asserted-by":"publisher","first-page":"9464","DOI":"10.1038\/s41467-024-53706-3","volume":"15","author":"S Punyawatthananukool","year":"2024","unstructured":"Punyawatthananukool S, Matsuura R, Wongchang T, et al. Prostaglandin E2-EP2\/EP4 signaling induces immunosuppression in human cancer by impairing bioenergetics and ribosome biogenesis in immune cells. Nat Commun. 2024;15:9464.","journal-title":"Nat Commun"},{"key":"4521_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/srep06538","volume":"4","author":"X Bai","year":"2014","unstructured":"Bai X, Wang J, Guo Y, et al. Prostaglandin E2 stimulates \u03b21-integrin expression in hepatocellular carcinoma through the EP1 receptor\/PKC\/NF-\u03baB pathway. Sci Rep. 2014;4:6538.","journal-title":"Sci Rep"},{"key":"4521_CR21","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/aps.2012.13","volume":"33","author":"J Jin","year":"2012","unstructured":"Jin J, Chang Y, Wei W, et al. Prostanoid EP1 receptor as the target of (-)-epigallocatechin-3-gallate in suppressing hepatocellular carcinoma cells in vitro. Acta Pharmacol Sin. 2012;33:701\u20139.","journal-title":"Acta Pharmacol Sin"},{"issue":"3","key":"4521_CR22","first-page":"1203","volume":"42","author":"X Sun","year":"2018","unstructured":"Sun X, Li Q. Prostaglandin EP2 receptor: novel therapeutic target for human cancers (review). Int J Mol Med. 2018;42(3):1203\u201314.","journal-title":"Int J Mol Med"},{"key":"4521_CR23","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1248\/bpb.b22-00104","volume":"45","author":"K Fukushima","year":"2022","unstructured":"Fukushima K, Fujino H. Identification and characterization of human colorectal cancer cluster predominantly expressing EP3 prostanoid receptor subtype. Biol Pharm Bull. 2022;45:698\u2013702.","journal-title":"Biol Pharm Bull"},{"key":"4521_CR24","first-page":"2343","volume":"62","author":"N Kundu","year":"2022","unstructured":"Kundu N, Fulton AM. Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer. Can Res. 2022;62:2343\u20136.","journal-title":"Can Res"},{"key":"4521_CR25","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/j.1349-7006.2006.00275.x","volume":"97","author":"N Niho","year":"2006","unstructured":"Niho N, Kitamura T, Takahashi M, et al. Suppression of azoxymethane induced colon cancer development in rats by a cyclooxygenase-1 selective inhibitor, mofezolac. Cancer Sci. 2006;97:1011\u20134.","journal-title":"Cancer Sci"},{"key":"4521_CR26","first-page":"680","volume":"87","author":"MG Perrone","year":"2014","unstructured":"Perrone MG, Malerba P, Uddin M, et al. PET radiotracer [18F]-P6 selectively targeting COX-1 as a novel biomarker in ovarian cancer: preliminary investigation. Eur J Med Chem. 2014;87:680\u20139.","journal-title":"Eur J Med Chem"},{"key":"4521_CR27","first-page":"351","volume":"24","author":"H Jeong","year":"2010","unstructured":"Jeong H, Kim J, Choi H, et al. Induction of cells growth arrest and apoptosis cell death in human breast cancer MCF-7 cells by the COX-1 inhibitor FR122047. Oncol Rep. 2010;24:351\u20136.","journal-title":"Oncol Rep"},{"key":"4521_CR28","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/ijc.1376","volume":"93","author":"J Rozic","year":"2001","unstructured":"Rozic J, Chakraborty C, Lala P. Cycloxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int J Cancer. 2001;93:497\u2013506.","journal-title":"Int J Cancer"},{"key":"4521_CR29","doi-asserted-by":"publisher","first-page":"302","DOI":"10.2174\/1389450119666180803121737","volume":"20","author":"N Totoczko-Iwaniuk","year":"2019","unstructured":"Totoczko-Iwaniuk N, Dziemianczyk-Pakiela D, Nowaszewska BK, et al. Celecoxib in cancer therapy and prevention\u2013review. Curr Drug Targets. 2019;20:302\u201315.","journal-title":"Curr Drug Targets"},{"key":"4521_CR30","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.2217\/nnm-2021-0086","volume":"16","author":"AF Khafaga","year":"2012","unstructured":"Khafaga AF, Shamma R, Abdeen A, et al. Celecoxib repurposing in cancer therapy: mocecular mechanism and nano,edicine-based delivery technologies. Nanomedicine. 2012;16:1691\u2013791.","journal-title":"Nanomedicine"},{"key":"4521_CR31","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ejca.2022.05.019","volume":"171","author":"J Zhang","year":"2022","unstructured":"Zhang J, Gao HF, Yang C, et al. Prevention of taxane-associated acute pain syndrome with etoricoxib for patients with breast cancer: a phase II randomised trial. Eur J Cancer. 2022;171:150\u201360.","journal-title":"Eur J Cancer"},{"issue":"32","key":"4521_CR32","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.2174\/092986710793205408","volume":"17","author":"MG Perrone","year":"2010","unstructured":"Perrone MG, Scilimati A, Simone L, Vitale P. Selective COX-1 inhibition: a therapeutic target to be reconsidered. Curr Med Chem. 2010;17(32):3780\u201391.","journal-title":"Curr Med Chem"},{"key":"4521_CR33","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/ijc.20109","volume":"110","author":"J Noguera","year":"2004","unstructured":"Noguera J, Amengual I, Pujol J. Dose of refocixib in colorectal cancer. Int J Cancer. 2004;110:309\u201310.","journal-title":"Int J Cancer"},{"key":"4521_CR34","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.1200\/JCO.2006.09.2791","volume":"25","author":"K O\u2019Byrne","year":"2007","unstructured":"O\u2019Byrne K, Danson S, Dunlop D, et al. Combination therapy with gefitinib and rofecoxib in patients with platinum pretreated relapsed non small-cell lung cancer. J Clin Oncol. 2007;25:3266\u201373.","journal-title":"J Clin Oncol"},{"key":"4521_CR35","doi-asserted-by":"publisher","first-page":"439","DOI":"10.4196\/kjpp.2022.26.6.439","volume":"26","author":"N Trang","year":"2022","unstructured":"Trang N, Yoo H. Antitumor effects of valdecoxib on hypopharyngeal squamous carcinoma cells. Korean J Physiol Pharmacol. 2022;26:439\u201346.","journal-title":"Korean J Physiol Pharmacol"},{"key":"4521_CR36","first-page":"7","volume":"16","author":"C Wan-Ling","year":"2024","unstructured":"Chang WL, Yang KC, Peng JY, Hong CL, Li PC, Chye SM, et al. Parecoxib enhances resveratrol against human colorectal cancer cell through Akt and TXNDC5 inhibition and MAPK regulation. Nutrients. 2024;16:7\u201318.","journal-title":"Nutrients"},{"issue":"4","key":"4521_CR37","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.3892\/ol.2016.5017","volume":"12","author":"Q Zhao","year":"2016","unstructured":"Zhao Q, Wang Z, Wang Z, Wu L, Zhang W. Aspirin may inhibit angiogenesis and induce autophagy by inhibiting mTOR signaling pathway in murine hepatocarcinoma and sarcoma models. Oncol Lett. 2016;12(4):2804\u201310.","journal-title":"Oncol Lett"},{"issue":"20","key":"4521_CR38","doi-asserted-by":"publisher","first-page":"6267","DOI":"10.1158\/1078-0432.CCR-17-0242","volume":"23","author":"X Dai","year":"2017","unstructured":"Dai X, Yan J, Fu X, Pan Q, Sun D, Xu Y, et al. Aspirin inhibits cancer metastasis and angiogenesis via targeting heparanase. Clin Cancer Res. 2017;23(20):6267\u201378.","journal-title":"Clin Cancer Res"},{"key":"4521_CR39","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s12079-018-00499-y","volume":"13","author":"G Maity","year":"2019","unstructured":"Maity G, Chakraborty J, Grosh A, Haque I, Banerjee S, Banerjee SK.\u00a0 Aspirin suppresses tumor cell-induced angiogenesis and their incongruity. J Cell Commun Signal. 2019;13:491\u2013502.","journal-title":"J Cell Commun Signal"},{"key":"4521_CR40","doi-asserted-by":"publisher","first-page":"e380","DOI":"10.1016\/j.wneu.2018.08.080","volume":"120","author":"SE Navone","year":"2018","unstructured":"Navone SE, Guarnaccia L, Cordiglieri C, Cris\u00e0 FM, Caroli M, Locatelli M, et al. Aspirin affects tumor angiogenesis and sensitizes human glioblastoma endothelial cells to temozolomide, bevacizumab, and sunitinib, impairing vascular endothelial growth factor-related signaling. World Neurosurg. 2018;120:e380\u201391.","journal-title":"World Neurosurg"},{"key":"4521_CR41","first-page":"383","volume":"9","author":"A Goel","year":"2023","unstructured":"Goel A, Chang DK, Ricciardiello L, Gasche C, Boland CR. A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells. Clin Cancer Res. 2023;9:383\u201390.","journal-title":"Clin Cancer Res"},{"key":"4521_CR42","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.biopha.2017.08.085","volume":"95","author":"J Ma","year":"2017","unstructured":"Ma J, Cai Z, Wei H, Liu X, Zhao Q, Zhang T. The anti-tumor effect of aspirin: what we know and what we expect. Biomed Pharmacother. 2017;95:656\u201361.","journal-title":"Biomed Pharmacother"},{"key":"4521_CR43","first-page":"624","volume":"16","author":"AR Munkarah","year":"2009","unstructured":"Munkarah AR, Uddin S, Hussain A, Al-Harbi S, Al-jom-mah N, Saed G, et al. Aspirin induces apoptosis in ovarian cancer cells via inhibition of Akt activity and downregulation of Cox-2 expression. Int J Gynecol Cancer. 2009;16:624\u201394.","journal-title":"Int J Gynecol Cancer"},{"key":"4521_CR44","first-page":"732","volume":"12","author":"X Lu","year":"2018","unstructured":"Lu X, Xing Z, Lu D, Liang X, Huang Z, Yang H, et al. Effect of aspirin on the proliferation and apoptosis of human adrenal cortical cancer cells. Chin J Endo Metab. 2018;12:732\u20137.","journal-title":"Chin J Endo Metab"},{"key":"4521_CR45","doi-asserted-by":"publisher","first-page":"4227","DOI":"10.3748\/wjg.14.4227","volume":"14","author":"MY Lai","year":"2008","unstructured":"Lai MY, Huang JA, Liang ZH, Jiang HX, Tang GD. Mechanisms underlying aspirin-mediated growth inhibition and apoptosis induction of cyclooxygenase-2 negative colon cancer cell line SW480. World J Gastroenterol. 2008;14:4227\u201333.","journal-title":"World J Gastroenterol"},{"key":"4521_CR46","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.11591","volume":"9","author":"J Guo","year":"2021","unstructured":"Guo J, Zhu Y, Yu L, Li Y, Guo J, Cai J, et al. Aspirin inhibits tumor progression and enhances cisplatin sensitivity in epithelial ovarian cancer. PeerJ. 2021;9:e11591.","journal-title":"PeerJ"},{"key":"4521_CR47","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv170","volume":"107","author":"D Ait Ouakrim","year":"2015","unstructured":"Ait Ouakrim D, Dashti SG, Chau R, Buchanan DD, Clendenning M, Rosty C, et al. Aspirin, ibuprofen, and the risk of colorectal cancer in Lynch syndrome. J Natl Cancer Inst. 2015;107:djv170.","journal-title":"J Natl Cancer Inst"},{"key":"4521_CR48","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1158\/1078-0432.CCR-07-4362","volume":"14","author":"M Lu","year":"2008","unstructured":"Lu M, Strohecker A, Chen F, Kwan T, Bosman J, Jordan VC, et al. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels. Clin Cancer Res. 2008;14:3168\u201376.","journal-title":"Clin Cancer Res"},{"key":"4521_CR49","volume":"8","author":"Q Zhang","year":"2017","unstructured":"Zhang Q, Zhu B, Li Y. Resolution of cancer-promoting inflammation: a new approach for anticancer therapy. Front Immunol. 2017;8:71.","journal-title":"Front Immunol"},{"key":"4521_CR50","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.intimp.2011.11.021","volume":"12","author":"M Hussain","year":"2012","unstructured":"Hussain M, Javeed A, Ashraf M, Zhao Y, Mukhtar MM, Rehman MU. Aspirin and immune system. Int Immunopharmacol. 2012;12:10\u201320.","journal-title":"Int Immunopharmacol"},{"key":"4521_CR51","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1200\/JCO.2016.70.7547","volume":"35","author":"T Hamada","year":"2017","unstructured":"Hamada T, Cao Y, Qian ZR, Masugi Y, Nowak JA, Yang J, et al. Aspirin use and colorectal cancer survival according to tumor CD274 (programmed cell death 1 ligand 1) expression status. J Clin Oncol. 2017;35:1836\u201344.","journal-title":"J Clin Oncol"},{"key":"4521_CR52","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1111\/1759-7714.13433","volume":"11","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Lv C, Dong Y, Yang Q. Aspirin-targeted PD-L1 in lung cancer growth inhibition. Thorac Cancer. 2020;11:1587\u201393.","journal-title":"Thorac Cancer"},{"key":"4521_CR53","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/4664651","author":"X Xiao","year":"2022","unstructured":"Xiao X, Zeng S, Li Y, Li L, Zhang J. Aspirin suppressed PD-L1 expression through suppressing KAT5 and subsequently inhibited PD-1 and PD-L1 signaling to attenuate OC development. J Oncol. 2022. https:\/\/doi.org\/10.1155\/2022\/4664651.","journal-title":"J Oncol"},{"key":"4521_CR54","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/s41586-025-08626-7","volume":"640","author":"J Yang","year":"2025","unstructured":"Yang J, Yamashita-Kanemaru Y, Morris BI, Contursi A, Trajkovski D, Xu J, et al. Aspirin prevents metastasis by limiting platelet TXA(2) suppression of T cell immunity. Nature. 2025;640:1052\u201361.","journal-title":"Nature"},{"key":"4521_CR55","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1093\/carcin\/bgab117","volume":"43","author":"R Xu","year":"2022","unstructured":"Xu R, Yan Y, Zheng X, Zhang H, Chen W, Li H, et al. Aspirin suppresses breast cancer metastasis to lung by targeting anoikis resistance. Carcinogenesis. 2022;43:104\u201314.","journal-title":"Carcinogenesis"},{"key":"4521_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13578-017-0198-7","volume":"8","author":"J Ying","year":"2018","unstructured":"Ying J, Zhou HY, Liu P, You Q, Kuang F, Shen YN, et al. Aspirin inhibited the metastasis of colon cancer cells by inhibiting the expression of toll-like receptor 4. Cell Biosci. 2018;8:1.","journal-title":"Cell Biosci"},{"key":"4521_CR57","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1111\/j.1349-7006.2010.01655.x","volume":"101","author":"M Bhattacharyya","year":"2010","unstructured":"Bhattacharyya M, Girish GV, Ghosh R, Chakraborty S, Sinha AK. Acetyl salicylic acid (aspirin) improves synthesis of maspin and lowers incidence of metastasis in breast cancer patients. Cancer Sci. 2010;101:2105\u20139.","journal-title":"Cancer Sci"},{"key":"4521_CR58","first-page":"559","volume":"13","author":"R Harris","year":"2005","unstructured":"Harris R, Beeb-donk J, Doss H, Burr DD. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of no-selective COX-2 blockade. Onocol Rep. 2005;13:559\u201383.","journal-title":"Onocol Rep"},{"key":"4521_CR59","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/ijc.35331","volume":"156","author":"A Lam","year":"2025","unstructured":"Lam A, Hao Z, Yiu K, Chan S, Chan F, Sung J, et al. Long-term use of low-dose aspirin for cancer prevention: a 20-year longitudinal cohort study of 1,506,525 Hong Kong residents. Int J Cancer. 2025;156:230\u20139.","journal-title":"Int J Cancer"},{"key":"4521_CR60","first-page":"527","volume":"18","author":"C Coleman","year":"2012","unstructured":"Coleman C, Limone B, Sobieraj D, Lee S, Roberts MS, Kaur R, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm. 2012;18:527\u201339.","journal-title":"J Manag Care Pharm"},{"key":"4521_CR61","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1158\/1940-6207.CAPR-11-0391","volume":"5","author":"AT Chan","year":"2012","unstructured":"Chan AT, Arber N, Burn J, Chia WK, Elwood P, Hull MA, et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res. 2012;5:164\u201378.","journal-title":"Cancer Prev Res"},{"key":"4521_CR62","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1093\/bjs\/znad231","volume":"110","author":"D Shah","year":"2023","unstructured":"Shah D, De Re A, Ton J. Aspirin chemoprevention in colorectal cancer: network meta-analysis of low, moderate, and high doses. Br J Sur. 2023;110:1691\u2013702.","journal-title":"Br J Sur"},{"key":"4521_CR63","doi-asserted-by":"publisher","first-page":"40389","DOI":"10.18632\/oncotarget.16315","volume":"8","author":"L Lu","year":"2017","unstructured":"Lu L, Shi L, Zeng J, Wen Z. Aspirin as a potential modality for the chemoprevention of breast cancer: a dose-response meta-analysis of cohort studies from 857,831 participants. Oncotarget. 2017;8:40389\u2013404001.","journal-title":"Oncotarget"},{"key":"4521_CR64","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/CEJ.0000000000000098","volume":"24","author":"E Yiannakopoulou","year":"2015","unstructured":"Yiannakopoulou E. Aspirin and NSAIDs for breast cancer chemoprevention. Eur J Cancer Prev. 2015;24:416\u201321.","journal-title":"Eur J Cancer Prev"},{"key":"4521_CR65","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1158\/1055-9965.EPI-16-1027","volume":"26","author":"CJ Smith","year":"2017","unstructured":"Smith CJ, Dorsey TH, Tang W,\u00a0 Jordan SV, Loffredo CA, Ambs S. Aspirin use reduce the risk of aggressive prostate cancer and disease recurrence in Africa-America men. Cancer Epidemiol Biomarkers Prev. 2017;26:845\u201353.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"4521_CR66","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s00011-025-02091-8","volume":"74","author":"N Unver","year":"2025","unstructured":"Unver N, Uluturk S, Tavukcuoglu E, Yilmaz ED, Kaymaz Y, esendagli G. The impact of aspirin on PDL-1 expression and alteration of M2 polarization in on-small cell lung cancer. Inflamm Res. 2025;74:124.","journal-title":"Inflamm Res"},{"key":"4521_CR67","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/1940-6207.CAPR-15-0126","volume":"8","author":"J Patrick","year":"2015","unstructured":"Patrick J, Sahasrabuddhe V, Chan A, Alavanja M, Beane-Freeman LE, Buring JE, et al. NSAID use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: the liver cancer pooling project. Cancer Prev Res. 2015;8:1156\u201362.","journal-title":"Cancer Prev Res"},{"key":"4521_CR68","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1186\/s12885-018-4156-5","volume":"18","author":"Y Qiao","year":"2018","unstructured":"Qiao Y, Yang T, Gan Y, Li W, Wang C, Gong Y, et al. Associations between aspirin use and risk of cancers: a meta-analysis of observational studies. BMC Cancer. 2018;18:288.","journal-title":"BMC Cancer"},{"key":"4521_CR69","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1007\/s10620-025-09042-7","volume":"70","author":"S Rifkin","year":"2025","unstructured":"Rifkin S, Montalvan-Sanchez E, Norwood D, Estevez-Ordonez D, Montalvan-Sanchez D,\u00a0 et al. Aspirin use is protective against gastric cancer in a high-incidence region of central America. Dig Dis Sci. 2025;70:3126\u201334.","journal-title":"Dig Dis Sci"},{"key":"4521_CR70","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1136\/gutjnl-2024-333329","volume":"74","author":"J Tan","year":"2025","unstructured":"Tan J, Mao X, Cheng H, Seto WK, Leung WK, Cheung KS. Aspirin is associated with low risk of pancreatic cancer and cancer-related mortality in patients with diabetes mellitus. Gut. 2025;74:603\u201312.","journal-title":"Gut"},{"key":"4521_CR71","doi-asserted-by":"publisher","first-page":"4598573","DOI":"10.1155\/2022\/4598573","volume":"2022","author":"S Guangshun","year":"2022","unstructured":"Guangshun S, Guoquiang S, Xin C, Xiangyi K, Wubin Z, Zhitao L, et al. Meloxicam inhibit hepatocellular carcinoma progression and enhances the sensitivity of immunotherapy via the MicriRNA-200\/PD-L1 pathway. J Oncol. 2022;2022:4598573.","journal-title":"J Oncol"},{"key":"4521_CR72","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/BF02940318","volume":"13","author":"B Xin","year":"2027","unstructured":"Xin B, Yokoyama Y, Shigeto T, Mizunuma H. Anti-tumor effect of non-steroidal anti-inflammatory drugs on human ovarian cancers. Pathol Oncol Res. 2027;13:365\u20139.","journal-title":"Pathol Oncol Res"},{"key":"4521_CR73","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.pain.2003.09.003","volume":"107","author":"A Fox","year":"2004","unstructured":"Fox A, Medhurst S, Courade J, Glatt M, Dawson J, Urban L, et al. Anti-hyperalgesic activity of the Cox-2 inhibitors lumiracoxib in a model of bone cancer pain in rat. Pain. 2004;107:33\u201340.","journal-title":"Pain"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04521-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04521-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04521-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T09:02:25Z","timestamp":1789549345000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04521-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":73,"alternative-id":["4521"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04521-3","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"assertion":[{"value":"2 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study is a literature review of basic and clinical research regarding the prophylactic and therapeutic effects of aspirin on cancer. The work focuses on a research project evaluated by the Ethics, Research, and Biosafety Commission of the National Institute of Public Health of Mexico (IDs: 1525, 1484). Informed consent is not required, as this is a literature-based study.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The review article based exclusively on previously published data and does not involve human participants or animals, not required ethical approval.","order":3,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}